Loading...
Market
Government response to puberty blockers and cancer risk study by end of 2024?
2
Resolution / Starting Odds
Implement new regulations • 25%
Conduct further research • 25%
No action taken • 25%
Other • 25%
Official government statements or policy changes reported by credible news sources
Story
Study Links Puberty Blockers to 26.5x Higher Testicular Cancer Risk
Nov 24, 2024, 01:49 AM
New evidence suggests that long-term treatment with puberty blockers and cross-sex hormones may significantly increase the risk of testicular cancer. A study involving 458 men found that they are 26.5 times more likely to develop testicular cancer after undergoing such treatments. Testicular cancer rates are 26.5x HIGHER in males seeking orchiectomies. This raises serious concerns about the safety and ethical implications of using these treatments in young individuals.
View original story
Similar markets
Proven safe and effective • 25%
Proven ineffective • 25%
Proven unsafe • 25%
Inconclusive results • 25%
Positive outcome • 25%
Negative outcome • 25%
Inconclusive outcome • 25%
Trials not completed • 25%
Support the ruling • 25%
Oppose the ruling • 25%
Neutral stance • 25%
Other • 25%
Safe and effective • 25%
Unsafe • 25%
Inconclusive • 25%
Trial not completed • 25%
Positive outcome • 25%
Negative outcome • 25%
Inconclusive • 25%
Trial not completed • 25%
Allowed with parental consent • 25%
Allowed without parental consent • 25%
Not allowed • 25%
Other • 25%
Leaked to media • 33%
Disclosed by NIH • 33%
Not disclosed • 34%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
No Action Taken • 25%
Publication Mandated • 25%
Funding Reallocation • 25%
Other Outcome • 25%